Court Report

By Sherri Oslick --

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Human Genome Sciences Inc. v. Genentech Inc. et al.
1:11-cv-00082; filed January 25, 2011 in the District Court of Delaware

• Plaintiff:  Human Genome Sciences Inc.
• Defendants:  Genentech Inc.; City of Hope

Declaratory judgment of non-infringement, invalidity, and unenforceability of U.S. Patent No. 6,331,415 ("Methods of Immunoglobulins, Vectors, and Transformed Host Cells for Use Therein," issued December 18, 2001) based on HGS's manufacture and sale of its Benlysta® product (belimumab, under development for the treatment of seropositive patients with systemic lupus erythematosus).  View the complaint here.

Warner Chilcott Co. LLC et al. v. Teva Pharmaceuticals USA Inc.
1:11-cv-00081; filed January 24, 2011 in the District Court of Delaware

• Plaintiffs:  Warner Chilcott Co. LLC; Hoffmann-La Roche Inc.
• Defendant:  Teva Pharmaceuticals USA Inc.

Infringement of U.S. Patent No. 7,718,634 ("Method of Treatment Using Bisphosphonic Acid," issued May 18, 2010), licensed to Warner Chilcott, following a Paragraph IV certification as part of Teva's filing of an ANDA to manufacture a generic version of Warner Chilcott's Once-a-Month Actonel® (risedronate sodium, used to treat and prevent postmenopausal osteoporosis).  View the complaint here.

Orion Corp. v. Mylan Pharmaceuticals Inc.
1:11-cv-00078; filed January 24, 2011 in the District Court of Delaware

Infringement of U.S. Patent No. 5,446,194 ("Pharmacologically active catechol derivatives," issued August 29, 1995) following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Orion's Comtan® (entacapone, used in the treatment of Parkinson's Disease).  View the complaint here.

Daiichi Sankyo Inc. et al. v. Watson Pharmaceuticals Inc. et al.
1:11-cv-00074; filed January 21, 2011 in the District Court of Delaware

• Plaintiffs:  Daiichi Sankyo Inc.; Genzyme Corp.
• Defendants:  Watson Pharmaceuticals Inc.; Watson Pharma Inc.; Watson Laboratories Inc. (NV)

Infringement of U.S. Patent No. 5,693,675 ("Alkylated Amine Polymers," issued December 2, 1997) following a Paragraph IV certification as part of Watson's filing of an ANDA to manufacture a generic version of plaintiffs' Welchol® (colesevelam hydrochloride, used to treat primary hyperlipidemia and type 2 diabetes mellitus).  View the complaint here.

Fresenius Medical Care Holdings, Inc. v. Zydus Pharmaceuticals USA, Inc.
1:11-cv-10110; filed January 21, 2011 in the District Court of Massachusetts

• Plaintiffs:  Fresenius Medical Care Holdings, Inc.
• Defendants:  Zydus Pharmaceuticals USA, Inc.

Infringement of U.S. Patent No. 6,576,665 ("Encapsulated Calcium Acetate Caplet and a Method for Inhibiting Gastrointestinal Phosphorous Absorption," issued June 10, 2003) following a Paragraph IV certification as part of Zydus' filing of an ANDA to manufacture a generic version of Fresenius' PhosLo® GelCaps (calcium acetate, used to treat renal failure).  View the complaint here.

Comments

[AM]

Hi

Do you know the number of the patent under which Novartis Vaccines have sued Medimmune (AstraZenca), Biogen and Alexion

[Novartis Vaccines & Diagnostics Inc. v. MedImmune LLC, 11-00084, U.S. District Court, District of Delaware (Wilmington)]

[Sherri]

That would be U.S. 5,688,688.

[AM]

Many thanks